ClinicalTrials.gg
CompletedNCT04292730Updated Jan 26, 2021Results posted

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

A Phase 3 interventional study of Remdesivir and Standard of Care in COVID-19, sponsored by Gilead Sciences. Completed at 184 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,113
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Enrollment
9th of 40
1,113 · median 283
Started
2020
with 26 others
Phase 3
17 of 40
2 open now
Registered
5th of 40
by date
Lead sponsor
6 of 40
Gilead Sciences

Among the 40 studies testing remdesivir in COVID-19, this one is the 9th largest by enrollment, is one of 27 that started in 2020, is one of 17 in phase 3, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Willing and able to provide written prior to performing study procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and \< 18 years of age) prior to performing study procedures. For participants ≥ 12 and \< 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures
  • Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test ≤ 4 days before randomization
  • Currently hospitalized and requiring medical care for COVID-19
  • Peripheral capillary oxygen saturation (SpO2) > 94% on room air at screening
  • Radiographic evidence of pulmonary infiltrates

Key Exclusion Criteria:

  • Participation in any other clinical trial of an experimental treatment for COVID-19
  • Concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2
  • Requiring mechanical ventilation at screening
  • (ALT) or aspartate aminotransferase (AST) > 5 X (ULN)
  • \< 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age {Cockcroft 1976} and Schwartz Formula for participants \< 18 years of age

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,113 participants (actual)

Study arms

  • Experimental
    Part A: Remdesivir (RDV), 5 Days

    Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.

    Drug: Remdesivir · Drug: Standard of Care

  • Experimental
    Part A: Remdesivir, 10 Days

    Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.

    Drug: Remdesivir · Drug: Standard of Care

  • Active comparator
    Part A: SOC Therapy

    Participants will receive continued standard of care therapy.

    Drug: Standard of Care

  • Experimental
    Part B: Extension Treatment, Remdesivir 10 Days

    Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.

    Drug: Remdesivir · Drug: Standard of Care

Interventions

  • Administered as an intravenous infusion

    Also known as: GS-5734™, Veklury®

  • DrugStandard of Care

    Standard of Care Treatment for COVID-19 Infection

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11

    Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of "1" was used for all days on or after the date of death; score of "7" was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.

    Time frame: Day 11

Secondary outcomes

  1. Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.

    Time frame: First dose date up to last dose date (maximum: 10 days) plus 30 days

07

Results

Posted Jan 26, 2021

Participant flow

Participants were enrolled at study sites in the United States, Europe, and Asia. The first participant was screened on 15 March 2020. The last study visit occurred on 26 June 2020.

Participant flow — Overall Study
MilestonePart A: Remdesivir (RDV) for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 Days
Started199197200517
Completed179176178437
Not completed20212280
Withdrew: Lost to follow-up8121248
Withdrew: Death22412
Withdrew: Withdrew consent2256
Withdrew: Non-compliance with study drug0100
Withdrew: Protocol violation0010
Withdrew: Randomized but not treated84014

Outcome measures

PrimaryPart A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11

Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of "1" was used for all days on or after the date of death; score of "7" was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.

Time frame:
Day 11
Reported as:
Number · percentage of participants
Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11
percentage of participantsPart A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC Therapy
Score: 10.01.02.0
Score: 20.00.52.0
Score: 32.60.03.5
Score: 43.76.25.5
Score: 519.922.823.0
Score: 63.74.74.0
Score: 770.264.860.0
Statistical analysis
  • Part A: Remdesivir for 5 Days vs Part A: SOC Therapy · Proportional odds model · p = 0.0174 (P-value was calculated using proportional odds model with treatment as the independent variable.) · Odds ratio (or): 1.65 · 95% CI 1.092 to 2.483
  • Part A: Remdesivir for 10 Days vs Part A: SOC Therapy · Proportional odds model · p = 0.1826 (P-value was calculated using proportional odds model with treatment as the independent variable.) · Odds ratio (or): 1.31 · 95% CI 0.880 to 1.952
  • Part A: Remdesivir for 5 Days vs Part A: SOC Therapy · Proportional odds model · p = 0.0168 (P-value was calculated using proportional odds model with treatment as the independent variable and baseline clinical status as a nominal covariate.) · Odds ratio (or): 1.65 · 95% CI 1.095 to 2.497
  • Part A: Remdesivir for 10 Days vs Part A: SOC Therapy · Proportional odds model · p = 0.2186 (P-value was calculated using proportional odds model with treatment as the independent variable and baseline clinical status as a nominal covariate.) · Odds ratio (or): 1.29 · 95% CI 0.862 to 1.917
SecondaryPart A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.

Time frame:
First dose date up to last dose date (maximum: 10 days) plus 30 days
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsPart A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC Therapy
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)51.3 (44.0 to 58.6)58.5 (51.3 to 65.6)46.5 (39.4 to 53.7)
Statistical analysis
  • Part A: Remdesivir for 5 Days vs Part A: SOC Therapy · Fisher Exact · p = 0.3633 (P-value was calculated from the Fisher exact test to compare each RDV group and the SOC group.) · Difference in the percentages: 4.8 · 95% CI -5.2 to 14.7
  • Part A: Remdesivir for 10 Days vs Part A: SOC Therapy · Fisher Exact · p = 0.0201 (P-value was calculated from the Fisher exact test to compare each RDV group and the SOC group.) · Difference in the percentages: 12.0 · 95% CI 1.6 to 21.8

Adverse events

Collected over First dose date up to the last dose date (maximum: 10 days for Part A, 11 days for Part B) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Remdesivir for 5 Days2/191 (1%)9/191 (4.7%)41/191 (21.5%)
Part A: Remdesivir for 10 Days3/193 (1.6%)10/193 (5.2%)42/193 (21.8%)
Part A: SOC Therapy4/200 (2%)18/200 (9%)30/200 (15%)
Part B: Extension Treatment, Remdesivir for 10 Days13/503 (2.6%)40/503 (8%)113/503 (22.5%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPart A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 Days
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1911/1935/2004/503
Respiratory distressRespiratory, thoracic and mediastinal disorders0/1912/1932/2001/503
Cardiac arrestCardiac disorders0/1910/1932/2000/503
Respiratory failureRespiratory, thoracic and mediastinal disorders1/1910/1932/2001/503
Febrile neutropeniaBlood and lymphatic system disorders1/1910/1930/2000/503
Impaired healingGeneral disorders1/1910/1930/2000/503
Pneumonia bacterialInfections and infestations1/1910/1930/2000/503
Heart rate decreasedInvestigations1/1910/1930/2000/503
Cerebrovascular accidentNervous system disorders1/1910/1930/2000/503
Renal colicRenal and urinary disorders1/1910/1930/2000/503
Most frequent other events
Most frequent other events
EventPart A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 Days
NauseaGastrointestinal disorders19/19118/1936/20041/503
DiarrhoeaGastrointestinal disorders12/19110/19314/20028/503
HypokalaemiaMetabolism and nutrition disorders10/19113/1934/20023/503
HeadacheNervous system disorders10/19110/1935/20027/503
ConstipationGastrointestinal disorders8/1915/1939/20026/503

Baseline characteristics

Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group). Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.

Age, Customized
Age, Customized(Participants)Part A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 DaysTotal
Age, Categorical — < 65 Years142141142351776
Age, Categorical — >= 65 Years495258152311
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 DaysTotal
Female777575221448
Male114118125282639
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 DaysTotal
Race — American Indian or Alaska Native20136
Race — Asian34313761163
Race — Black353727107206
Race — Native Hawaiian or Pacific Islander11114
Race — White109107112260588
Race — Not Permitted5572138
Race — Other512155082
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 DaysTotal
Ethnicity — Hispanic or Latino254234156257
Ethnicity — Not Hispanic or Latino162144152325783
Ethnicity — Not Permitted47132246
Ethnicity — Missing00101
Region of Enrollment
Region of Enrollment(Participants)Part A: Remdesivir for 5 DaysPart A: Remdesivir for 10 DaysPart A: SOC TherapyPart B: Extension Treatment, Remdesivir for 10 DaysTotal
United States769985318578
Spain37283144140
Italy30232654133
United Kingdom79172760
South Korea74101637
Germany8681335
Singapore3691432
Hong Kong9117128
Switzerland456318
France21058
Taiwan51006
Netherlands30115
Japan00044
Sweden00033
08

Study locations

184 sites
  • Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue
    Anaheim, California 92806, United States
  • Alta Bates Summit Medical Center
    Berkeley, California 94609, United States
  • Mills-Peninsula Medical Center
    Burlingame, California 94010, United States
  • Eden Medical Center
    Castro Valley, California 94546, United States
  • Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway
    Downey, California 90241, United States
  • Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave
    Fontana, California 92335, United States
  • St Joseph Hospital Eureka
    Fortuna, California 95540, United States
  • Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave.
    Harbor City, California 90710, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave.
    Los Angeles, California 90034, United States
  • Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue
    Los Angeles, California 91365, United States
  • Mission Hospital Regional Medical Center
    Mission Viejo, California 92691, United States
  • Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue
    Moreno Valley, California 92555, United States
  • El Camino Hospital
    Mountain View, California 94040, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92658, United States
  • Kaiser Permanente Oakland Medical Center
    Oakland, California 94611, United States
  • Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue
    Ontario, California 91761, United States
  • The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange
    Orange, California 92868, United States
  • Kaiser Permanente Los Angeles Medical Center,13651 Willard Street
    Panorama City, California 91402, United States
  • Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue
    Riverside, California 92505, United States
  • Sutter Medical Center Sacramento, One Medical Plaza
    Roseville, California 95661, United States
  • Sutter Medical Center Sacramento
    Sacramento, California 95815, United States
  • Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue
    San Diego, California 92120-2507, United States
  • Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd
    San Diego, California 92123, United States
  • Kaiser Permanente Oakland Medical Center, 1200 El Camino Real
    San Francisco, California 94080, United States
  • California Pacific Medical Center-Infectious Disease Associates Medical Group
    San Francisco, California 94109, United States
  • Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd
    San Francisco, California 94115, United States
  • Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850
    San Jose, California 95119, United States
  • Kaiser Permanente Oakland Medical Center, 2500 Merced St
    San Leandro, California 94577, United States
  • Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway
    Santa Clara, California 95051, United States
  • Providence St. Johns Medical Center
    Santa Monica, California 90404, United States
  • Sutter Santa Rosa Regional Hospital
    Santa Rosa, California 95403, United States
  • Stanford Hospital
    Stanford, California 94305, United States
  • University of Colorado Denver, University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • SCL Health St. Joseph Hospital, 1375 East 19th Ave
    Denver, Colorado 80208, United States
  • SCL Health St. Joseph Hospital
    Denver, Colorado 80218, United States
  • Rose Medical Center
    Denver, Colorado 80220, United States
  • SCL Health St. Joseph Hospital, 200 Exempla Circle.
    Lafayette, Colorado 80026, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Kaiser Permanente Hawaii Moanalua Medical Center
    Honolulu, Hawaii 96819, United States
  • Cook County General Hospital
    Chicago, Illinois 60612, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • IU Health Methodist Hospital
    Indianapolis, Indiana 46077, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Tulane University
    New Orleans, Louisiana 70112, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham & Women's Hospital and Harvard Medical School
    Boston, Massachusetts 02115, United States
  • Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • The University of Michigan Hospitals and Health Systems
    Ann Arbor, Michigan 48109-5378, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin Healthcare
    Minneapolis, Minnesota 55415, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Providence St Patrick Hospital and International Heart Institute of MT Foundation
    Missoula, Montana 59802, United States
  • Darmouth-Hitchhock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Hackensack Medical Center
    Hackensack, New Jersey 07601, United States
  • Robert Wood Johnson University Hospital Somerset
    Hillsborough, New Jersey 08844, United States
  • Robert Wood Johnson University Hospital Somerset, 1 RWJ Place
    New Brunswick, New Jersey 08901, United States
  • Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue
    Newark, New Jersey 07112, United States
  • St. Joseph's University Medical Center
    Paterson, New Jersey 07503, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • James J. Peters Veterans Administration Medical Center
    Bronx, New York 10468, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States
  • Danbury Hospital
    Lagrangeville, New York 12540, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • North Shore University Hospital, 270-05 76th Ave
    New Hyde Park, New York 11040, United States
  • Icahn School of Medicine at Mount Sinai, 350 East 17th Street
    New York, New York 10003, United States
  • Icahn School of Medicine at Mount Sinai, 1000 10th Avenue
    New York, New York 10019, United States
  • Icahn School of Medicine at Mount Sinai, 440 West 114th St.
    New York, New York 10025, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Weill Cornell Medical College/NYU Presbyterian Hospital
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave
    Hillsboro, Oregon 97124, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Providence St. Vincent Medical Center
    Portland, Oregon 97225, United States
  • Kaiser Sunnyside Medical Center
    Portland, Oregon 97227, United States
  • Hospital of the University of Pennsylvania, 51 N. 31st Street
    Philadelphia, Pennsylvania 19104, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Prisma Health Richland Hospital
    Columbia, South Carolina 29203, United States
  • Prisma Health Richland Hospital, 701 Grove Road
    Greenville, South Carolina 29605, United States
  • The Liver Institute of Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • UT Southwestern Medical Center Amelia Court, HIV Research Clinic
    Dallas, Texas 75235, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd.
    Dallas, Texas 75390, United States
  • UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd
    Dallas, Texas 75390, United States
  • Baylor University Medical Center, 1400 8th Ave
    Fort Worth, Texas 76104, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Baylor University Medical Center, 2401 S. 31st St.
    Temple, Texas 76508, United States
  • University of Utah Health
    Salt Lake City, Utah 84132, United States
  • Virginia Hospital Center
    Arlington, Virginia 22205, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • VCU Health Medical Center
    Richmond, Virginia 23298, United States
  • Providence Medical Research Center
    Everett, Washington 98201, United States
  • Kadlec Regional Medical Center
    Kennewick, Washington 99336, United States

Showing the first 100 of 184 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. PubMed 32821939 ↗
  • Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962. PubMed 34350582 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Apr 2020, 1 month.

Results were first posted in Jan 2021, 8 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2020
First posted
Mar 3, 2020
StartActual
Mar 15, 2020
Primary completionActual
Apr 29, 2020
CompletionActual
Jun 26, 2020
Results first posted
Jan 26, 2021
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04292730
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 3, 2020
Start date
Mar 15, 2020
Primary completion
Apr 29, 2020
Completion
Jun 26, 2020
Results posted
Jan 26, 2021
Last update
Jan 26, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remdesivir

Start the discussion